Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
  • C07K16/3023—Lung
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
  • C07K14/70503—Immunoglobulin superfamily
  • C07K14/70539—MHC-molecules, e.g. HLA-molecules
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/46—Hybrid immunoglobulins
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P21/00—Preparation of peptides or proteins
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
  • C07K2317/41—Glycosylation, sialylation, or fucosylation
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/52—Constant or Fc region; Isotype
  • C07K2317/53—Hinge
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
  • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
  • C07K2317/622—Single chain antibody (scFv)
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
  • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
  • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
  • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Definitions

• the CMV has evolved to become a sublime parasite of the human genome and it is a potent immunogen and triggers strong immune responses from all arms of the immune system. This virus appears to be among the most immunodominant antigens known to the human immune system and stimulates CD8 -T-cell responses of unprecedented magnitude.
• the CMV "latency” depends on chronic immune suppression of CMV viruses rather than a change in the pattern of viral transcription (Moss & Khan, Human Immunology 65 (2004) 456-464).
• the antibody heavy chain hinge region polypeptide is selected from an antibody heavy chain hinge region polypeptide of a human antibody of the class IgG or the class IgE.
• a third linker peptide that has an amino acid sequence selected from SEQ ID NO: 12, 16, 17, 18, 21, 22, and 23, and - two polypeptide chains, which are linked by one or more disulfide bonds, wherein the first disulfide-linked polypeptide chain comprises in N- to C-terminal direction
• an antibody constant domain that is the complementary heavy or light chain constant domain to that comprised in the first disulfide-linked polypeptide chain.
• the virus-derived polypeptide comprises the amino acid sequence of SEQ ID NO: 01
• the first linker peptide comprises the amino acid sequence of SEQ ID NO: 21
• the second linker peptide comprises the amino acid sequence of SEQ ID NO: 22
• the third linker peptide comprises the amino acid sequence of SEQ ID NO: 12
• the human IgGl CH2 domain comprises the amino acid sequence of SEQ ID NO: 32 or 33
• the human IgGl CH3 domain of one disulfide-linked polypeptide comprises the amino acid sequence of SEQ ID NO: 35 and the human IgGl CH3 domain of the other disulfide-linked polypeptide comprises the amino acid sequence of SEQ ID NO: 36.
• a virus-derived peptide that has an amino acid sequence selected from SEQ ID NO: 01 to SEQ ID NO: 09
• a first linker peptide that has an amino acid sequence selected from SEQ ID NO: 16, 17, 18, 21, 22, and 23.
• a ⁇ 2 -microglobulin that has an amino acid sequence of SEQ ID NO: 10 or is a variant thereof comprising of from 1 to 10 amino acid exchanges, additions, and/or deletions,
• an antibody heavy chain hinge region polypeptide comprising an amino acid sequence selected from SEQ ID NO: 24 to SEQ ID NO: 30 and SEQ ID NO: 47-51,
• a human IgGl CH3 domain comprising an amino acid sequence selected from SEQ ID NO: 34, 35, and 36, wherein the fusion polypeptide is covalently bound either to the C-terminus or the N-terminus of the second disulfide-linked polypeptide chain, or
• SEQ ID NO: 35 and the human IgGl CH3 domain of the other disulfide-linked polypeptide comprises the amino acid sequence of SEQ ID NO: 36.
• the first linker peptide comprises the amino acid sequence of SEQ ID NO: 21, and/or
• the third linker peptide comprises the amino acid sequence of SEQ ID NO: 12, and/or
• the human IgGl CH2 domain comprises the amino acid sequence of SEQ ID NO: 1
• the human IgGl CH3 domain of one disulfide-linked polypeptide comprises the amino acid sequence of SEQ ID NO: 35 and the human IgGl CH3 domain of the other disulfide-linked polypeptide comprises the amino acid sequence of SEQ ID NO: 36.
• the virus-derived peptide is selected from the group comprising SEQ ID NO: 01 to SEQ ID NO: 09, SEQ ID NO: 52 to SEQ ID NO: 112, or is a variant thereof comprising of from 1 to 3 amino acid exchanges, additions, and/or deletions.
• One aspect as reported herein is a nucleic acid encoding the complex as reported herein.
• the nucleic acid comprises two to four expression cassettes comprising structural genes encoding polypeptides with different amino acid sequence.
• One aspect as reported herein is a host cell comprising the nucleic acid as reported herein.
• the complex is recovered from the cells or the cultivation medium and thereby the complex is produced.
• One aspect as reported herein is an immunoconjugate comprising the complex as reported herein and a cytotoxic agent.
• One aspect as reported herein is a pharmaceutical formulation comprising the complex as reported herein and optionally a pharmaceutically acceptable carrier.
• the pharmaceutical formulation further comprises an additional therapeutic agent.
• One aspect as reported herein is the complex as reported herein for use in attracting virus-specific cytotoxic T-cells of an individual to a target.
• One aspect as reported herein is the complex as reported herein for use in removal cancer cells or virus infected cells.
• One aspect as reported herein is the use of the complex as reported herein in the manufacture of a medicament.
• H460M2 cells incubated with one-armed peptide-P2- microglobulin-HLA-A0201-IgG-heavy chain + IgG-light chain + IgG-Fc complex, not stained;
• H460M2 cells incubated with one-armed peptide-P2- microglobulin-HLA-A0201-IgG-heavy chain + IgG-light chain + IgG-Fc complex at 37°C, stained with fluorescently labeled anti ⁇ human IgG> antibody;
• Cytotoxicity assay antigen binding complex as reported herein triggers lysis of H460M2 tumor cells through human CMV-specific T-cells.
• SEQ ID NO: 03 Human herpesvirus 4 derived peptide.
• SEQ ID NO: 05 Hepatitis-B-virus-derived peptide.
• SEQ ID NO: 06 Human T-cell lymphotropic virus type 1 derived peptide.
• SEQ ID NO: 07 V-jun Sarcoma Virus 17 Oncogene Homolog (JUN) derived peptide.
• SEQ ID NO: 09 Hepatitis-C-virus-derived peptide.
• SEQ ID NO: 11 Human HLA-A*0201 al - a3 chain amino acid sequence.
• SEQ ID NO: 26 Human IgG2 heavy chain hinge polypeptide amino acid sequence.
• SEQ ID NO: 28 Human IgG2 heavy chain hinge variant polypeptide amino acid sequence.
• SEQ ID NO: 32 Human IgGl CH2 domain L234A, L235A mutant amino acid sequence.
• SEQ ID NO: 35 Human IgGl CH3 domain knob variant amino acid sequence.
• SEQ ID NO: 36 Human IgGl CH3 domain hole variant amino acid sequence.
• SEQ ID NO: 37 Human IgGl Fc-region amino acid sequence.
• SEQ ID NO: 38 Human IgGl Fc-region L234A, L235A mutant amino acid sequence.
• SEQ ID NO: 40 Human IgGl Fc-region L234A, L235A mutant and knob variant amino acid sequence.
• SEQ ID NO: 41 Humanized anti-IGF-lR monoclonal light chain antibody amino acid sequence (kappa).
• SEQ ID NO: 43 Humanized anti-IGF-lR monoclonal heavy chain antibody amino acid sequence (IgGl L234A, L235A mutant and knob variant).
• an antibody variable domain that is the complementary heavy or light chain variable domain to that comprised in the first disulfide-linked polypeptide chain, or
• an antibody constant domain that is the complementary heavy or light chain constant domain to that comprised in the first disulfide-linked polypeptide chain.
• VH immunoglobulin heavy chain variable domain
• CHI immunoglobulin heavy chain first constant domain
• CL immunoglobulin light chain constant domain
• VL immunoglobulin light chain variable domain
• CL immunoglobulin light chain constant domain
• CHI immunoglobulin heavy chain first constant domain
• VH immunoglobulin heavy chain variable domain
• CHI immunoglobulin heavy chain first constant domain
• CL immunoglobulin light chain constant domain
• the light or heavy chain variable domain either alone or in combination with the respective complementary heavy or light chain variable domain specifically binds to an antigen
• the second disulfide-linked polypeptide chain comprises in N- to C-terminal direction an antibody heavy chain hinge region polypeptide, an immunoglobulin heavy chain second constant region (CH2), and an immunoglobulin heavy chain third constant region (CH3), wherein the fusion polypeptide is
• VH immunoglobulin heavy chain variable domain
• CHI immunoglobulin heavy chain first constant domain
• CL immunoglobulin light chain constant domain
• the light or heavy chain variable domain either alone or in combination with the respective complementary heavy or light chain variable domain specifically binds to an antigen
• the second disulfide-linked polypeptide chain comprises in N- to C -terminal direction
• an antibody variable domain that is the complementary heavy or light chain variable domain to that comprised in the first disulfide-linked polypeptide chain, or
• an antibody constant domain that is the complementary heavy or light chain constant domain to that comprised in the first disulfide-linked polypeptide chain.
• VL immunoglobulin light chain variable domain
• CL immunoglobulin light chain constant domain
• CHI immunoglobulin heavy chain first constant domain
• VH immunoglobulin heavy chain variable domain
• CHI immunoglobulin heavy chain first constant domain
• CL immunoglobulin light chain constant domain
• VL immunoglobulin light chain variable domain
• CL immunoglobulin light chain constant domain
• CHI immunoglobulin heavy chain first constant domain
• an antibody constant domain that is the complementary heavy or light chain constant domain to that comprised in the first disulfide-linked polypeptide chain.
• VL immunoglobulin light chain variable domain
• CL immunoglobulin light chain constant domain
• CHI immunoglobulin heavy chain first constant domain
• VH immunoglobulin heavy chain variable domain
• CHI immunoglobulin heavy chain first constant domain
• CL immunoglobulin light chain constant domain
• the complex is characterized in that it comprises
• an immunoglobulin light chain variable domain VL
• an immunoglobulin heavy chain variable domain VH
• the complex is characterized in that it comprises
• VL immunoglobulin light chain variable domain
• CL immunoglobulin light chain constant domain
• CHI immunoglobulin heavy chain first constant domain
• VL immunoglobulin light chain variable domain
• CL immunoglobulin light chain constant domain
• CHI immunoglobulin heavy chain first constant domain
• the complex is characterized in that it comprises
• VH immunoglobulin heavy chain variable domain
• CHI immunoglobulin heavy chain first constant domain
• CL immunoglobulin light chain constant domain
• VL immunoglobulin light chain variable domain
• CL immunoglobulin light chain constant domain
• CHI immunoglobulin heavy chain first constant domain
• VH immunoglobulin heavy chain variable domain
• CHI immunoglobulin heavy chain first constant domain
• CL immunoglobulin light chain constant domain
• one third polypeptide chain that comprises in N- to C-terminal direction an immunoglobulin variable domain complementary to the variable domain in the second polypeptide chain and a constant domain complementary to the constant domain in the second polypeptide chain, wherein the light or heavy chain variable domain of the fusion polypeptide and/or of the second polypeptide chain either alone or in combination with the respective complementary heavy or light chain variable domain specifically binds to an antigen, and wherein the first polypeptide chain and the second polypeptide chain are disulfide-linked.
• the T-cell-response eliciting peptide is a virus-derived peptide.
• the virus is selected from adenovirus, human herpesvirus 1, human herpesvirus 2, human herpesvirus 4 (Epstein-Barr virus), hepatitis-B-virus, hepatitis-C-virus, human cytomegalovirus, human immunodeficiency virus, human papillomavirus type 16, human papillomavirus type 18, human papillomavirus type 31, human papillomavirus type 33, human papillomavirus type 35, human papillomavirus type 39, human papillomavirus type 45, human papillomavirus type 51, human papillomavirus type 52, human papillomavirus type 56, human papillomavirus type 58, human papillomavirus type 59, human papillomavirus type 68, human papillo
• virus-derived peptide is selected from NLVPMVATV (SEQ ID NO: 01), SLYNTVATL (SEQ ID NO: 02), GLCTLVAML (SEQ ID NO: 03), GILGFVFTL (SEQ ID NO: 04), STNRQSGRQ (SEQ ID NO: 5), LLFGYPVYV (SEQ ID NO: 06), FAEGFVRAL (SEQ ID NO: 07), LIVIGILIL (SEQ ID NO: 08), or ILHTPGCV (SEQ ID NO: 09).
• the ⁇ 2 -microglobulin is human 2-microglobulin.
• the P2-microglobulin is consisting of the amino acid sequence of SEQ ID NO: 10.
• virus-derived peptide is fused to the ⁇ 2 -microglobulin via a first linker peptide.
• the P2-microglobulin is fused to the extracellular domain al of a class I MHC molecule via a second linker peptide.
• the extracellular domain a3 of a class I MHC molecule is fused to the polypeptide (either disulfide-linked or not disulfide-linked) via a third linker peptide.
• first, second, and third linker peptide is the same or different.
• the first linker peptide, the second linker peptide, and the third linker peptide are selected independently from each other from the amino acid sequences GS (SEQ ID NO: 12), GGS (SEQ ID NO: 13), GGGS (SEQ ID NO: 14), GGGSGGGS (SEQ ID NO: 15), GGGSGGGSGGGS (SEQ ID NO: 16), GGGSGGGSGGGSGGGS (SEQ ID NO: 17), GGGSGGGSGGGSGGGSGGGS (SEQ ID NO: 18), GGGGS (SEQ ID NO: 19), GGGGSGGGGS (SEQ ID NO: 20), GGGGSGGGGSGGGGS (SEQ ID NO: 21), GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 22), and GGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 23).
• the first linker peptide comprises the amino acid sequence of
• the second linker peptide comprises the amino acid sequence of SEQ ID NO: 22.
• the antibody heavy chain hinge region polypeptide is selected from an antibody heavy chain hinge region polypeptide of a human antibody of the class IgG or the class IgE.
• the antibody heavy chain hinge region polypeptide is selected from an antibody heavy chain hinge region polypeptide of a human antibody of the subclass IgGl, or IgG2, or IgG3, or IgG4.
• the antibody heavy chain hinge region polypeptide comprises or is consisting of the amino acid sequence of EPKSCDKTHTCPPCP (SEQ ID NO: 24), EPKSADKTHTCPPCP (SEQ ID NO: 25), ER CCVECPPCP (SEQ ID NO: 26), ER CAVECPPCP (SEQ ID NO: 27), ERKACVECPPCP (SEQ ID NO: 28), ELKTPLGDTTHTCPRCP (EPKSCDTPPPCPRCP) 3 (SEQ ID NO: 29), or ESKYGPPCPSCP (SEQ ID NO: 30).
• the first disulfide-linked polypeptide and/or the second disulfide-linked polypeptide comprises a CH2 domain and/or a CH3 domain of human origin.
• the CH2 domain and the CH3 of human origin is of a human antibody of the class IgG or IgE.
• the CH2 domain and the CH3 domain is of a human antibody of the subclass IgGl, or IgG2, or IgG3, or IgG4.
• the CH2 domain comprises the amino acid sequence of SEQ ID NO: 31.
• the CH2 domain is of a human antibody of the subclass IgGl or IgG2 and comprises at least one mutation of E233, L234, L235, G236, D265, D270, N297, E318, K320, K322, A327, A330, P331 and/or P329 (numbering according to the EU index of Kabat).
• the EU index of Kabat the EU index of Kabat
• CH2 domain is of a human antibody of the subclass IgGl or the human subclass IgG2 with the mutations L234A and L235A, and/or the mutations D265A and N297A, and/or contains the PVA236 mutation, and/or contains the mutation P329G.
• the CH2 domain is of a human antibody of the subclass IgGl with the mutations L234A and L235A, and/or P329G.
• the CH2 domain is of a human antibody of the subclass IgGl with the mutations L234A and L235A, and/or P329G.
• CH2 domain is of a human antibody of the subclass IgG4 with the mutations S228P and/or L235E.
• the CH2 domain comprises the amino acid sequence of SEQ ID NO: 32 or SEQ ID NO: 33.
• the CH3 domain comprises the amino acid sequence of SEQ ID NO: 34.
• the first disulfide-linked polypeptide comprises the amino acid sequence of SEQ ID NO: 35 and the second disulfide-linked polypeptide comprises the amino acid sequence of SEQ ID NO: 36.
• first disulfide-linked polypeptide comprises the amino acid sequence of SEQ ID NO: 39 and the second disulfide-linked polypeptide comprises the amino acid sequence of SEQ ID NO: 40.
• polypeptide chains which are linked by one or more disulfide bonds, are linked by two, or three, or four disulfide bonds.
• the complex is characterized in that it comprises
• a human IgGl CH3 domain comprising an amino acid sequence selected from SEQ ID NO: 35 or 36, and the second disulfide-linked polypeptide chain comprises an antibody heavy chain hinge region polypeptide, wherein the fusion polypeptide is
• the cytotoxicity assay was performed in the presence of CMV-specific CD8 + T-cells. It can be seen that complexes comprising a CMV-derived virus peptide induce the lysis/removal/disintegration of the target cells (see Figure 15 a) for monovalent antibody, Figure 15 b) for bivalent antibody). It can further be seen that the lysis of the target cells is highly specific as the incubation with complexes comprising an EBV-derived viral peptide ( Figure 15 b)) and control antibodies ( Figure 15 d) and e)) do not result in extensive cell lysis (the spontaneous lysis is about 3.5 %).
• the EC50 value for a complex comprising a CMV-derived peptide and a bivalent antibody is about 10 ng/ml corresponding to about 50 pM.
• the determined EC 50 value is independent from the target cell to effector cell ratio (see Figure 16; target cell to effector cell ratio from 1 :3 to 1 : 1 corresponding to an effective ratio of 1 :0.44 to 1 :0.14 (76 % of effector cells are CD8 positive and 19 % are CMV specific)).
• a complex as provided herein comprises an antigen binding pair of antibody variable domains.
• the variable domain has a dissociation constant (Kd) of ⁇ 10 nM, ⁇ 1 nM, ⁇ 0.1 nM, ⁇ 0.01 nM, or ⁇ 0.001 nM (e.g. 10 "8 M or less, e.g. from 10 "8 M to 10 "13 M, e.g., from 10 "9 M to
• Kd is measured using surface plasmon resonance assays.
• N-hydroxysuccinimide (NHS) according to the supplier's instructions.
• Antigen is diluted with 10 mM sodium acetate, pH 4.8, to 5 ⁇ g/ml (-0.2 ⁇ ) before injection at a flow rate of 5 ⁇ /minute to achieve approximately 10 response units (RU) of coupled protein.
• 1 M ethanolamine is injected to block unreacted groups.
• two-fold serial dilutions of Fab (0.78 nM to 500 nM) are injected in PBS with 0.05 % polysorbate 20 (TWEEN- 20TM) surfactant (PBST) at 25 °C at a flow rate of approximately 25 ⁇ /min.
• Association rates (kon) and dissociation rates (koff) are calculated using a simple one-to-one Langmuir binding model (BIACORE® Evaluation Software version
• the equilibrium dissociation constant (Kd) is calculated as the ratio koff/kon. See, e.g., Chen, Y., et al, J. Mol. Biol. 293 (1999) 865-881.
• complexes comprising two fusion polypeptide comprising a virus-derived peptide linked to a MHC class I protein complex, at least one variable domain, and a pair of hinge region derived disulfide-linked polypeptides is not possible in eukaryotic cells.
• a fusion polypeptide comprising a virus- derived peptide linked to a MHC class I protein cannot be present more than once and at least one antibody variable domain and one antibody constant domain has to be present in order to allow for the production and the secretion of the complex using eukaryotic cells.
• a complex comprising exactly one fusion polypeptide of a virus-derived peptide linked to a MHC class I protein, an antibody heavy chain hinge region, and at least one antibody variable domain and one antibody constant domain can be recombinantly produced in and secreted from eukaryotic cells.
• the at least one constant domain is either an antibody heavy chain constant domain 1 (CHI) or an antibody light chain constant domain (CL).
• cell lines capable of producing defucosylated antibodies include Led 3 CHO cells deficient in protein fucosylation (Ripka, J., et al., Arch. Biochem. Biophys. 249 (1986) 533-545; US 2003/0157108; and WO 2004/056312, especially at Example 11), and knockout cell lines, such as alpha- 1 ,6-fucosyltransferase gene, FUT8, knockout CHO cells (see, e.g., Yamane-Ohnuki, N., et al, Biotech. Bioeng. 87 (2004) 614-622; Kanda, Y., et al, Biotechnol. Bioeng. 94 (2006) 680-688; and WO 2003/085107).
• Fc-region variants are further provided with bisected oligosaccharides, e.g., in which a biantennary oligosaccharide attached to the Fc- region is bisected by GlcNAc.
• Such variants may have reduced fucosylation and/or improved ADCC function. Examples of such antibody variants are described, e.g., in WO 2003/011878; US 6,602,684; and US 2005/0123546.
• Fc-region variants with at least one galactose residue in the oligosaccharide attached to the Fc-region are also provided. Such Fc-region variants may have improved CDC function.
• Clq binding assays may also be carried out to confirm that the antibody is unable to bind Clq and hence lacks CDC activity. See, e.g., Clq and C3c binding ELISA in WO 2006/029879 and WO 2005/100402.
• a CDC assay may be performed (see, for example, Gazzano-Santoro, H., et al., J. Immunol. Methods 202 (1996) 163-171; Cragg, M.S., et al, Blood 101 (2003) 1045-1052; and Cragg, M.S. and Glennie, M.J., Blood 103 (2004) 2738-2743).
• Fc-regions with reduced effector function include those with substitution of one or more of Fc-region residues 234, 235, 238, 265, 269, 270, 297, 327 and 329 (see e.g. US 6,737,056).
• Such Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including the so-called "DANA" Fc mutant with substitution of residues 265 and 297 to alanine (US 7,332,581).
• Certain Fc-region variants with improved or diminished binding to FcRs are described. (See, e.g., US 6,737,056; WO 2004/056312, and Shields, R.L., et al, J. Biol. Chem. 276 (2001) 6591-6604).
• Such Fc-region variants include those with substitutions at one or more of Fc-region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434, e.g., substitution of Fc-region residue 434 (US 7,371,826). See also Duncan, A.R. and Winter, G., Nature 322 (1988) 738-740; US 5,648,260;
• Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water.
• the polymer may be of any molecular weight, and may be branched or unbranched.
• the number of polymers attached to the antibody may vary, and if more than one polymer is attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of the antibody to be improved, whether the antibody derivative will be used in a therapy under defined conditions, etc.
• conjugates of a complex and non-proteinaceous moiety that may be selectively heated by exposure to radiation are provided.
• the non-proteinaceous moiety is a carbon nanotube (Kam, N.W., et al., Proc. Natl. Acad. Sci. USA 102 (2005) 11600-11605).
• the radiation may be of any wavelength, and includes, but is not limited to, wavelengths that do not harm ordinary cells, but which heat the non-proteinaceous moiety to a temperature at which cells proximal to the antibody-non-proteinaceous moiety are killed.
• a host cell comprises (e.g., has been transformed with): (1) a vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and an amino acid sequence comprising the VH of the antibody, or (2) a first vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and a second vector comprising a nucleic acid that encodes an amino acid sequence comprising the VH of the antibody.
• the host cell is eukaryotic, e.g. a Chinese Hamster Ovary (CHO) cell or lymphoid cell (e.g., Y0, NS0, Sp2/0 cell).
• a method of making a complex as reported herein comprises culturing a host cell comprising a nucleic acid encoding the polypeptides of the complex, as provided above, under conditions suitable for expression of the polypeptides and formation of the complex, and optionally recovering the complex from the host cell (or host cell culture medium).
• nucleic acid encoding the polypeptides of the complex e.g., as described above, are isolated and inserted into one or more vectors for further cloning and/or expression in a host cell.
• nucleic acid may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody).
• Suitable host cells for the expression of glycosylated complexes are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculo viral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells.
• TM4 cells as described, e.g., in Mather, J.P., Biol. Reprod. 23 (1980) 243-252); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells, as described, e.g., in Mather, J.P., et al, Annals N.Y. Acad. Sci.
• TM4 cells as described, e.g., in Mather, J.P., Biol. Reprod. 23 (1980) 243-252
• monkey kidney cells CV1; African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (
• compositions of a complex as described herein are prepared by mixing such complex having the desired degree of purity with one or more optional pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed.) (1980)), in the form of lyophilized formulations or aqueous solutions.
• Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyl dimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m- cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as poly(vinylpyrrolidone); amino acids such as glycine, glutamine, asparagine, histidine, arg
• sHASEGP human soluble PH-20 hyaluronidase glycoproteins, such as rhuPH20 (HYLENEX , Baxter International, Inc.).
• rhuPH20 HYLENEX , Baxter International, Inc.
• Certain exemplary sHASEGPs and methods of use, including rhuPH20, are described in US 2005/0260186 and US 2006/0104968.
• a sHASEGP is combined with one or more additional glycosaminoglycanases such as chondroitinases.
• additional glycosaminoglycanases such as chondroitinases.
• Exemplary lyophilized antibody formulations are described in US 6,267,958.
• the formulation herein may also contain more than one active ingredients as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other.
• active ingredients are suitably present in combination in amounts that are effective for the purpose intended.
• the formulations to be used for in vivo administration are generally sterile. Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes.
• the invention provides a complex as reported herein for use in a method of treating an individual having cancer or a viral infection comprising administering to the individual an effective amount of the complex as reported herein.
• the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, e.g., as described below.
• the invention provides for the use of a complex as reported herein in the manufacture or preparation of a medicament.
• the medicament is for treatment of cancer or viral infections.
• the medicament is for use in a method of treating cancer or viral infections comprising administering to an individual having cancer or a chronic viral infection an effective amount of the medicament.
• the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent.
• the medicament is for the removal of cancer cells or for the removal of virus infected cells.
• the medicament is for use in a method of removal of cancer cells or removal of virus infected cells in an individual comprising administering to the individual an amount effective of the medicament to remove cancer cells or to remove virus infected cells.
• An "individual" according to any of the above embodiments may be a human.
• the invention provides a method for treating cancer or a viral infection. In one embodiment, the method comprises administering to an individual having such cancer or viral infection an effective amount of a complex as reported herein. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent.
• An "individual" according to any of the above embodiments may be a human.
• the invention provides a method for removal of cancer cells or virus infected cells in an individual.
• the method comprises administering to the individual an effective amount of a complex as reported herein to remove cancer cells or virus infected cells.
• an "individual" is a human.
• the invention provides pharmaceutical formulations comprising any of the complexes as reported herein, e.g., for use in any of the above therapeutic methods.
• a pharmaceutical formulation comprises any of the complexes as reported herein and a pharmaceutically acceptable carrier.
• a pharmaceutical formulation comprises any of the complexes as reported herein and at least one additional therapeutic agent.
• a complex of the invention (and any additional therapeutic agent) can be administered by any suitable means, including parenteral, intrapulmonary, and intranasal, and, if desired for local treatment, intralesional administration.
• Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Dosing can be by any suitable route, e.g. by injections, such as intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic. Various dosing schedules including but not limited to single or multiple administrations over various time -points, bolus administration, and pulse infusion are contemplated herein.
• the appropriate dosage of a complex of the invention (when used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease to be treated, the type of complex, the severity and course of the disease, whether the complex is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the complex, and the discretion of the attending physician.
• the complex is suitably administered to the patient at one time or over a series of treatments.
• about 1 ⁇ g/kg to 15 mg/kg (e.g. 0.5 mg/kg - lO mg/kg) of complex can be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion.
• One typical daily dosage might range from about 1 ⁇ g/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment would generally be sustained until a desired suppression of disease symptoms occurs.
• One exemplary dosage of the antibody would be in the range from about 0.05 mg/kg to about 10 mg/kg.
• one or more doses of about 0.5 mg/kg, 2.0 mg/kg, 4.0 mg/kg or 10 mg/kg (or any combination thereof) may be administered to the patient.
• Such doses may be administered intermittently, e.g. every week or every three weeks (e.g. such that the patient receives from about two to about twenty, or e.g. about six doses of the antibody).
• One aspect as reported herein is the complex as reported herein for use in a method of treating a cancer or a viral infection in a patient, wherein the complex is to be administered before, simultaneously or after the immunization of the patient with the virus-derived peptide comprised in the complex.
• One aspect as reported herein is the use of a complex as reported herein for the manufacture of a medicament for the treatment of cancer or a viral infection in combination with immunization against the virus-derived peptide comprised in the complex.
• the virus-derived peptide as contained in the complex is administered first to the individual to be treated. At a certain time span later, i.e. between 4 days and 28 days, the complex as reported herein is administered to the individual.
• an article of manufacture containing materials useful for the treatment, prevention and/or diagnosis of the disorders described above comprises a container and a label or package insert on or associated with the container.
• Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc.
• the containers may be formed from a variety of materials such as glass or plastic.
• the container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
• At least one active agent in the composition is a complex of the invention.
• the label or package insert indicates that the composition is used for treating the condition of choice.
• the article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises a complex of the invention; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent.
• the article of manufacture in this embodiment of the invention may further comprise a package insert indicating that the compositions can be used to treat a particular condition.
• the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically- acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate- buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
• BWFI bacteriostatic water for injection
• phosphate- buffered saline such as bac
• PBL were isolated by Ficoll gradient centrifugation from human donor blood (Greiner bio-one, Cat. No. 227290). PBLs were cultured in RPMI supplemented with 5 % human serum (Sigma Cat. No. H2520), 2 mM L-glutamine (PAN Biotech, Cat. No. P04-80100), 100 ⁇ g/ml Penicillin/Streptomycin (Roche, Cat. No. 14001100).
• T-cells were co-cultured with stimulator cells, which are peptide-pulsed autologous primary PBLs of the same donor (either freshly prepared or derived from frozen stocks).
• the stimulator cells were pulsed with the peptide as described above. After the two hours of peptide incubation the PBLs were irradiated (4000 rad; STS GmbH OB29 Nr.9510-5) and washed twice in culture medium without peptide. The re-stimulation was carried out in 96 well plates round bottom plates. 8 x 10 4 to 1 x 10 5 stimulator cells were used per 96 well. Cells from the primary culture were washed twice with culture medium, resuspended in 200 ⁇ culture medium and 80 ⁇ were transferred to each well of the stimulator cells. After 3 days 20 U/ml
• IL-2 25 ng/ml IL-7 and 25 ng/ml IL-15 were added. Cells did proliferate and were expanded every 2 to 3 days in new wells with fresh medium.
• Cells were stained for CD8 expression (BD, Cat. No. 345772) and CMV-specific T-cell receptors (Prolmmune, Cat. No. F008-4A-E) and analyzed in FACS.
• PBLs peripheral blood lymphocytes
• the cells were labeled with a FITC-conjugated anti-CD8 antibody (BD, Cat. No. 345772) combined with APC-conjugated Pro5 pentamer (Prolmmune, Cat. No. F008-4A-E) to stain T-cells which carry a T-cell receptor (TCR) recognizing MHC-class I (HL A- A* 0201) loaded with CMV-derived peptide
• TCR T-cell receptor
• Acute lymphoblastic leukemia cells carry the A*0201 HLA-A allele.
• MN60 cells (1 x 10 6 cells/ml) were incubated with 50 ⁇ g/ml CMV pp65 peptide (SEQ ID NO: 01) for 45 minutes under cell culture conditions (37 °C, 5 % C0 2 , 80 % humidity). The incubation results in a peptide exchange in the HLA-A* 0201 peptide binding groove.
• the peptide exchanged MN60 cells were centrifuged and diluted to a density of 1 x 10 6 cells/ml with PBS (PanBiotech, Cat. No.
• MN60 cells are FITC-positive. Effector cells are FITC-negative. Dead cells are PI positive, alive cells are Pi-negative. It can be seen that more than 85 % of the MN60 cells are alive when they are not loaded with the CMV-derived peptide (Q2 and Q4).
• Figure 5b the FACS analysis of MN60 cells loaded with CMV-derived peptide is shown.
• Flow Cytometric Analysis to analyze the cytolytic capability of stimulated CTLs through lysis of MN60 tumor cells loaded with CMV peptide depending on the effector to target cell ratio The cytotoxic assay was performed as described above. Different effector cell to target cell ratios were applied ranging from 0.5 effector cells per target cell to four effector cells per target cell (see Figure 6). Incubation time was four hours. MN60 cells which were not loaded with the CMV-derived peptide do not show an increased number of dead cells with an increased effector to target ratio, i.e. ranging from 8 % to 13 % with ratio 0.5 : 1 to 4 : 1.
• plasmid DNA was extracted according to the manufacturer's protocol (High speed Maxi kit, Qiagen, Cat. No. 12663). The resulting plasmid DNA was eluted in 1 ml TE buffer and
• DNA concentration was determined by spectrophotometric measurement (Epoch, BioTek).
• the final expression vector comprised the following elements:
• HLA-A*0201 ⁇ xl - a3 SEQ ID NO: 11
• the gel electrophoresis was carried out at 125 V for 90 minutes.
• the gels were stained with Simply Blue Safe Stain (Invitrogen, Cat. No. LC6065). Results
• Ig heavy chain (IgGl-L234A,
• 124 target cells (lxl 0 5 cells/ml) were seeded in cell culture media (RPMI 1640 supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM NEAA, and 10 % (v/w) FCS) on WillCo Glass Bottom Dishes (FA. WillCo Wells BV, REF GWST-3522) for 24 to 48 hours. WillCo Glass Bottom Dishes were pre- coated with 50 ⁇ g/ml poly-L-lysine hydrochloride (Sigma Aldrich, Cat # P2658) per dish for 30 min. After coating the dishes were thoroughly rinsed with sterile tissue culture grade water and dried for two hours.
• the antigen binding complex comprising one [CMV-pp65-peptide]-[linker l]-[p2-microglobulin]- [linker 2]-[HLA-A-al-a2-a3]-[linker 3]-[IgGl-L234A, L235A mutant with hole variation] fusion polypeptide, one IgGl-L234A, L235A mutant Fc-region knob variant disulfide-linked polypeptide and one Ig light chain, wherein the complex specifically binds to human IGF-1R as reported herein (see e.g.
• Example 3 was added in a final concentration of 5 ⁇ g/ml in 3 mM K + Krebs Ringer HEPES Buffer pH 7.3 (supplemented with 0.5 mM DL-dithiothreitol, 1 mM ascorbic acid, and 4 mM glutathione).
• T-cells were added in a target cell to effector cell ration of 1 : 10. Imaging was performed for 4 hours with a Zeiss Axiovert 135 microscope. Results
• Lysis is mediated by human CMV-specific T- cells (small cells either round shaped, white arrow, or amoeboid migrating cells, black arrow).
• 124 cells are incubated with the complex at a concentration of 5 ⁇ g/ml and human CMV-specific T-cells (pre-activated with HLA-A0201 + /CMV peptide pulsed APCs). Time lapse is indicated below the respective picture. Note the interaction of the 124 cells with the T-cells at 56 min and 76 min and subsequently the collapse of the 124 cell after 125 min.
• Figure 1 microscope imaging of a control showing the absence of lysis of 124 3T3 cells (large adherently growing cells, white arrowhead) through human CMV-specific T-cells (small cells either round shaped, white arrow or amoeboid migrating cells, black arrow) in the absence of an antigen binding complex as reported herein.
• 124 cells are incubated with specific cytotoxic T-cells (pre- activated with HLA-A0201 + /CMV peptide pulsed APCs). Time lapse is indicated below the respective picture.
• 124 cells were diluted to lxl 0 6 cells/ml in cell culture media (RPMI 1640, 2 mM L-glutamine, 1 mM Sodium pyruvate, 0.1 mM NEAA, 10 % (v/w) FCS) and 50 ⁇ (2xl0 4 cells/well) were pipetted in each well of an Xcelligence 96well plate to a final volume of 100 ⁇ and cultivated for 24 hours (37 °C, 8 % C0 2 , 80 % humidity). After 24 hours the medium was removed and the cells were washed with 200 ⁇ AIM-V (Serum Free Medium (Invitrogen) T-cell medium (Cat-No): 12055-083) medium.
• AIM-V Sem Free Medium (Invitrogen) T-cell medium (Cat-No): 12055-083 medium.
• the antigen binding complex comprising one [CMV-pp65- peptide]- [linker l]-[p2-microglobulin]-[linker 2]-[HLA-A-al-a2-a3]-[linker 3]- [IgGl-L234A, L235A mutant with hole variation] fusion polypeptide, one IgGl- L234A, L235A mutant Fc-region knob variant disulfide-linked polypeptide and one Ig light chain, wherein the complex specifically binds to human IGF-IR, as reported herein was added to the washed target cells in a final concentration of 1 ⁇ g/ml in AIM-V medium. Effector cells in the respectable ratio were added in
• AIM-V media to a final volume of 150 ⁇ .
• Afucosylated IgGl monoclonal antibody directed against human IGF-IR (anti-IGF-lR antibody-afucosylated) and non- binding human anti-digoxigenin antibody (anti-digoxygenin antibody) served as Isotype control and specific antibody control, respectively. Measurement was performed for 6 to 9 hours respectively with the Xcelligence System (Roche).
• Tumor cells were incubated for 4 hours with 1 ⁇ g/ml of the complex comprising one [CMV-pp65 -peptide] -[linker l]-[p2-microglobulin]-[linker 2]-[HLA-A-al-a2- a3]-[linker 3]-[IgGl-L234A, L235A mutant with hole variation] fusion polypeptide, one IgGl-L234A, L235A mutant Fc-region knob variant disulfide- linked polypeptide and one Ig light chain, wherein the complex specifically binds to human IGF-IR, and specific T-cells in the respective ratio (1 : 1.5 to 1 :0.5) (see Figure 12). Percentage of lysis is denoted above the respective bars. Afucosylated IgGl monoclonal antibody directed against human IGF-IR (MAB IGF-lR-afu) did not trigger a significant tumor cell lysis.
• the complex as reported herein triggers lysis of 124 3T3 target cells through human CMV-specific T-cells.
• Target cells were incubated for 4 hours with 1 ⁇ g/ml of an antigen binding complex comprising one [CMV-pp65-peptide]-[linker l]-[p2-microglobulin]- [linker 2]-[HLA-A-al-a2-a3]-[linker 3]-[IgGl-L234A, L235A mutant with hole variation] fusion polypeptide, one IgGl-L234A, L235A mutant Fc-region knob variant disulfide-linked polypeptide and one Ig light chain, wherein the complex specifically binds to human IGF-IR, and specific T-cells in the respective ratio
• IGF-IR positive lung adenocarcinoma cell line H460M2 was incubated with 1 ⁇ g/ml of a complex comprising an hCMV-derived peptide and an anti-IGF-lR antibody and human CMV-specific CD8-positive T-cells at a low effector cell to target cell ratio (1.5 to 0.5 specific T-cells per tumor cell).
• Control antibody was a glyco-engineered anti-IGF-lR antibody.
• the incubation time was 6 hours. The incubation with complex results in a potent removal of H460M2 tumor cells.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Immunology (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Biochemistry (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Zoology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Cell Biology (AREA)
• Gastroenterology & Hepatology (AREA)
• Wood Science & Technology (AREA)
• Virology (AREA)
• Toxicology (AREA)
• Microbiology (AREA)
• General Engineering & Computer Science (AREA)
• Biotechnology (AREA)
• Epidemiology (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Peptides Or Proteins (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (16)

Applications Claiming Priority (2)

Publications (1)

Family

ID=46319142

Family Applications (1)

Country Status (24)

Cited By (15)

Families Citing this family (21)

Citations (68)

Family Cites Families (6)

• 2012
  • 2012-06-19 ES ES12728091.5T patent/ES2667864T3/es active Active
  • 2012-06-19 AU AU2012274127A patent/AU2012274127B2/en not_active Ceased
  • 2012-06-19 EA EA201400046A patent/EA201400046A1/ru unknown
  • 2012-06-19 MX MX2013014869A patent/MX354663B/es active IP Right Grant
  • 2012-06-19 US US13/526,718 patent/US20130011394A1/en not_active Abandoned
  • 2012-06-19 SG SG2013086061A patent/SG195077A1/en unknown
  • 2012-06-19 KR KR1020137033957A patent/KR102038155B1/ko not_active Expired - Fee Related
  • 2012-06-19 WO PCT/EP2012/061734 patent/WO2012175508A1/en not_active Ceased
  • 2012-06-19 PH PH1/2013/502499A patent/PH12013502499A1/en unknown
  • 2012-06-19 PE PE2013002879A patent/PE20141212A1/es not_active Application Discontinuation
  • 2012-06-19 PL PL12728091T patent/PL2723773T3/pl unknown
  • 2012-06-19 AR ARP120102174A patent/AR086982A1/es unknown
  • 2012-06-19 CN CN201910510484.7A patent/CN110229235A/zh active Pending
  • 2012-06-19 BR BR112013029746-8A patent/BR112013029746B1/pt not_active IP Right Cessation
  • 2012-06-19 EP EP12728091.5A patent/EP2723773B1/en active Active
  • 2012-06-19 CN CN201280033335.2A patent/CN103649125A/zh active Pending
  • 2012-06-19 CA CA2835772A patent/CA2835772C/en not_active Expired - Fee Related
  • 2012-06-19 JP JP2014516311A patent/JP6246711B2/ja not_active Expired - Fee Related
  • 2012-06-20 TW TW101122112A patent/TWI563087B/zh not_active IP Right Cessation
• 2013
  • 2013-11-01 CO CO13259753A patent/CO6801646A2/es unknown
  • 2013-11-18 IL IL229486A patent/IL229486B/en active IP Right Grant
  • 2013-11-21 CR CR20130609A patent/CR20130609A/es unknown
  • 2013-12-18 CL CL2013003634A patent/CL2013003634A1/es unknown
  • 2013-12-20 EC ECSP13013098 patent/ECSP13013098A/es unknown
• 2014
  • 2014-01-08 MA MA36656A patent/MA35604B1/fr unknown
• 2016
  • 2016-03-23 US US15/078,962 patent/US20160362500A1/en not_active Abandoned
• 2017
  • 2017-08-10 JP JP2017155048A patent/JP6542303B2/ja not_active Expired - Fee Related
• 2020
  • 2020-01-27 US US16/773,846 patent/US20200157239A1/en not_active Abandoned
• 2021
  • 2021-05-13 US US17/320,046 patent/US20220089769A1/en not_active Abandoned

Patent Citations (73)

Non-Patent Citations (57)

Also Published As

Similar Documents

Legal Events